A Phase I Study of the Safety, Tolerability, and Pharmacokinetics of Intravenous CCI-779 [temsirolimus] Given Once Daily for 5 Days Every 2 Weeks to Patients With Advanced Solid Tumors
Phase of Trial: Phase I
Latest Information Update: 08 Aug 2012
At a glance
- Drugs Temsirolimus (Primary)
- Indications Cancer metastases; Glioma; Solid tumours
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- 18 Sep 2005 New trial record.